✦ LIBER ✦

The DAVID trial and its implications: Where do we go from here?

✍ Scribed by Brian Olshansky

Book ID: 107534949
Publisher: Springer
Year: 2003
Tongue: English
Weight: 122 KB
Volume: 5
Category: Article
ISSN: 1523-3782
DOI: 10.1007/s11886-003-0094-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Where do we go from here?

✍ Ross, Griff T. 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB

Where Do We Go From Here?

✍ George E. Vaillant 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Where do we go From Here?

✍ Alison Cameron 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Where Do We Go from Here?

✍ Gregory R. Peterson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

Sorafenib: Where do we go from here?

✍ Abby B. Siegel; Sonja K. Olsen; Arthur Magun; Robert S. Brown Jr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB 👁 1 views

The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely

Editorial: Where do we go from here?

✍ Bob Tricker 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB